ID: ALA312640

Max Phase: Preclinical

Molecular Formula: C33H38N4O10

Molecular Weight: 650.68

Molecule Type: Small molecule

Representations

Canonical SMILES:  C[C@H]1OC(c2cccc(O)c2O)=NC1C(=O)N(CCCCNC(=O)c1cccc(O)c1O)CCCCNC(=O)c1cccc(O)c1O

Standard InChI:  InChI=1S/C33H38N4O10/c1-19-26(36-32(47-19)22-11-8-14-25(40)29(22)43)33(46)37(17-4-2-15-34-30(44)20-9-6-12-23(38)27(20)41)18-5-3-16-35-31(45)21-10-7-13-24(39)28(21)42/h6-14,19,26,38-43H,2-5,15-18H2,1H3,(H,34,44)(H,35,45)/t19-,26?/m1/s1

Standard InChI Key:  IGHCLDWQZMZWPQ-ICCFGIFFSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 650.68

Molecular Weight (Monoisotopic): 650.2588

AlogP: 2.70

#Rotatable Bonds: 14

Polar Surface Area: 221.48

Molecular Species: NEUTRAL

HBA: 11

HBD: 8

#RO5 Violations: 3

HBA (Lipinski): 14

HBD (Lipinski): 8

#RO5 Violations (Lipinski): 3

CX Acidic pKa: 7.98

CX Basic pKa: 0.14

CX LogP: 4.59

CX LogD: 4.48

Aromatic Rings: 3

Heavy Atoms: 47

QED Weighted: 0.09

Np Likeness Score: -0.17

References

1. Bergeron RJ, Xin MG, Weimar WR, Smith RE, Wiegand J..  (2001)  Significance of asymmetric sites in choosing siderophores as deferration agents.,  44  (15): [PMID:11448229] [10.1021/jm010019s]

Source

Source(1):

• Scientific Literature